Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 1
2019 1
2020 1
2023 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Performance of the Aortix Device in Acute Decompensated Heart Failure and Cardiorenal Syndrome.
Cowger JA, Basir MB, Baran DA, Hayward CS, Rangaswami J, Walton A, Tita C, Minear S, Hakemi E, Klein L, Cheng R, Wu R, Mohanty BD, Heuring JJ, Neely E, Shah P; Aortix CRS Pilot Study Investigators. Cowger JA, et al. JACC Heart Fail. 2023 Nov;11(11):1565-1575. doi: 10.1016/j.jchf.2023.06.018. Epub 2023 Oct 4. JACC Heart Fail. 2023. PMID: 37804307 Free article. Clinical Trial.

Pump therapy averaged 4.6 1.6 days, yielding net fluid losses of 10.7 6.5 L (P < 0.001) and significant (P < 0.01) reductions in central venous pressure (change from baseline: -8.5 mm Hg [25th-75th percentile: -3.5 to -10.0 mm Hg]), pulmonary capillary wedge pres

…

Pump therapy averaged 4.6 1.6 days, yielding net fluid losses of 10.7 6.5 L (P < 0.001) and significant (P < 0.01) reductio

…
Vitamin D Supplementation and Risk of Hypercalciuria in Stone Formers.
Ganji MR, Shafii Z, Hakemi MS. Ganji MR, et al. Iran J Kidney Dis. 2019 Jan;13(1):27-31. Iran J Kidney Dis. 2019. PMID: 30851716
Also, the median level of serum parathyroid hormone was significantly reduced from 53 ng/L (interquartile range, 22 ng/L to 163 ng/L) to 38 ng/L (interquartile range, 16 ng/L to 102 ng/L; P < .001). ...
Also, the median level of serum parathyroid hormone was significantly reduced from 53 ng/L (interquartile range, 22 ng/L to 16 …
Inhibitory Effect of Genistein on PLC/PRF5 Hepatocellular Carcinoma Cell Line.
Dastjerdi MN, Kavoosi F, Valiani A, Esfandiari E, Sanaei M, Sobhanian S, Hakemi MG, Mobarakian M. Dastjerdi MN, et al. Int J Prev Med. 2015 Jun 17;6:54. doi: 10.4103/2008-7802.158914. eCollection 2015. Int J Prev Med. 2015. PMID: 26180625 Free PMC article.
METHODS: Cells were treated with various doses of GE (1, 5, 10, 25, 50, 75, and 100 muM/L) at different times (24, 48, and 72 h) and the MTT assay was commonly used. Furthermore, cells were treated with single dose of GE (25 muM) at different times and flow cytometry was p …
METHODS: Cells were treated with various doses of GE (1, 5, 10, 25, 50, 75, and 100 muM/L) at different times (24, 48, and 72 h) and …
The effect of vitamin E supplementation on biomarkers of endothelial function and inflammation among hemodialysis patients: A double-blinded randomized clinical trial.
Pirhadi-Tavandashti N, Imani H, Ebrahimpour-Koujan S, Samavat S, Hakemi MS. Pirhadi-Tavandashti N, et al. Complement Ther Med. 2020 Mar;49:102357. doi: 10.1016/j.ctim.2020.102357. Epub 2020 Feb 26. Complement Ther Med. 2020. PMID: 32147078 Clinical Trial.
However, no significant difference was observed between the two groups regarding the serum levels of hs-CRP (-0.15 0.19 mg/l vs. 0.02 0.12 mg/l; P = 0.32) and IL-6 (-0.03 0.1 pg/ml vs. - 0.06 0.11 pg/ml; P = 0.65). ...
However, no significant difference was observed between the two groups regarding the serum levels of hs-CRP (-0.15 0.19 mg/l vs. 0. …
Investigation on different levels of in vitro-in vivo correlation: gemfibrozil immediate release capsule.
Rouini MR, Ardakani YH, Mirfazaelian A, Hakemi L, Baluchestani M. Rouini MR, et al. Biopharm Drug Dispos. 2008 Sep;29(6):349-55. doi: 10.1002/bdd.620. Biopharm Drug Dispos. 2008. PMID: 18615873 Clinical Trial.
In vitro dissolution test methods with a standard paddle, round-bottomed vessel of 1 l capacity, and potassium phosphate buffer as the dissolution medium (referred to as conditions I, II and III, respectively) were developed. ...
In vitro dissolution test methods with a standard paddle, round-bottomed vessel of 1 l capacity, and potassium phosphate buffer as th …